This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Increasing molar activity by HPLC purification improves 68Ga-DOTA-NAPamide tumor accumulation in a B16/F1 melanoma xenograft model
- Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect
- Variation of Specific Activities of 68Ga-Aquibeprin and 68Ga-Avebetrin Enables Selective PET Imaging of Different Expression Levels of Integrins {alpha}5{beta}1 and {alpha}v{beta}3
- Induction of Apoptosis with Hybrids of Arg-Gly-Asp Molecules and Peptides and Antimitotic Effects of Hybrids of Cytostatic Drugs and Peptides
- Crucial Role for Somatostatin Receptor Subtype 2 in Determining the Uptake of [111In-DTPA-D-Phe1]Octreotide in Somatostatin Receptor-Positive Organs
- Peptide Receptor Radionuclide Therapy In Vitro Using [111In-DTPA0]Octreotide
- Peptide Receptor Imaging and Therapy
- Radiotherapy and Dosimetry of 64Cu-TETA-Tyr3-Octreotate in a Somatostatin Receptor-positive, Tumor-bearing Rat Model